The researchers found that median progression-free survival was 14.6 and 10.0 months for TACE with lenvatinib plus pembrolizumab and TACE plus placebo, respectively (hazard ratio, 0.66; 95 percent ...

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ...

Cipla share price declined 2 percent after the United States Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI). At 09:29am, Cipla was quoting ...

For information, the company have announced that the trial for pembrolizumab plus lenvatinib in endometrial cancer did not meet its primary endpoint and therefore they will no longer be pursuing a ...

At the awards night, Cipla took home a total of 4 metals across categories for its impressive work and creativity. The brand won 2 silver and 2 bronze metals across categories. Apart from Cipla ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Cipla: The pharma player has informed the exchanges that its manufacturing facility in Bengaluru's Virgonagar has received a Voluntary Action Indicated status from the USFDA. VA Tech Wabag ...

MG introduced the Majestor three-row SUV at the Bharat Mobility Expo in India. The new SUV is a basically rebadged Maxus/LDV D90. MG describes the Majestor as the “tallest, longest, and widest ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Your browser does not support the audio element. JSW MG Motor India has showcased the M9 MPV at the ongoing Auto Expo 2025. This will be the second product sold via ...